Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease



Status:Enrolling by invitation
Conditions:Gastrointestinal, Hepatitis
Therapuetic Areas:Gastroenterology, Immunology / Infectious Diseases
Healthy:No
Age Range:18 - 74
Updated:2/21/2019
Start Date:January 25, 2019
End Date:October 2019

Use our guide to learn which trials are right for you!

This study evaluates the effect of erythropoietin on the number and function of regulatory T
cells in adults with autoimmune hepatitis. Participants will receive a single dose of
erythropoietin, and then the investigators will collect blood at different time points for
analysis of regulatory T cell number and function.

There is data from the laboratory that erythropoietin helps stimulate regulatory T cells, a
type of immune cell which is thought to combat autoimmunity, but this study will look at
whether it does the same thing in adults with autoimmune hepatitis.

Inclusion Criteria:

- Diagnosis of autoimmune liver diseases (autoimmune hepatitis, autoimmune
cholangiopathy, or primary biliary cirrhosis or primary sclerosing cholangitis with
hepatic autoimmune liver disease or overlap syndrome) confirmed on liver biopsy

- Use of immunosuppressive therapy (prednisone, azathioprine, 6-mercaptopurine,
mycophenolate mofetil) for the treatment of the autoimmune liver disease

- Stable immunosuppression regimen at least 6 months prior to enrollment

- Ability to provide verbal and written informed consent

Exclusion Criteria:

- Diagnosis of decompensated cirrhosis (defined by presence of ascites, varices,
encephalopathy)

- Hemoglobin above average normal value (15.7 g/dL in men, 13.8 g/dL in women)

- Alanine aminotransferase greater than 2 times upper limit of normal (33 IU/L in men
and 25 IU/L in women)

- Uncontrolled hypertension with systolic blood pressure greater than or equal to 160 or
diastolic blood pressure greater than or equal to 100

- End-stage renal disease on hemodialysis

- History of venous thromboembolism including deep vein thromboses or pulmonary emboli

- History of stroke

- History of heart failure

- History of seizure disorder

- History of significant cardiovascular disease including a history of myocardial
infarction

- Active malignancy (untreated or undergoing therapy)

- History of pure red cell aplasia

- History of intolerance or allergy to erythropoietin

- Known hypersensitivity to mammalian cell-derived products

- Known hypersensitivity to human albumin

- Presence of vascular access

- Prior recipient of erythropoietin within 12 weeks of the study

- Patient unable to provide consent including infants, children, teenagers, prisoners,
cognitively impaired adults

- Non-English speaking

- Pregnancy
We found this trial at
2
sites
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
New York, New York
?
mi
from
New York, NY
Click here to add this to my saved trials